Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 64 Publications

13 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Cells were cultured with the indicated concentrations of PLS-123, rapamycin (Granta519 0.002 μM, Mino 0.001 μM, Z138 0.005 μM), and their combination for 48 h. The results are expressed as the mean of relative activity and S.D. from triplicate cultures. The results are representative of at least three similar experiments.

    Int J Cancer, 2018, 142(1):202-213. Rapamycin (Sirolimus) purchased from Selleck.

  • Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

    Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

    Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

  • Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

    2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

  • Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 MWXDfZRwfG:6aXOgRZN{[Xl? NGT6OG4yOCCwTR?= MVq3NkBp NXr6XIVoTE2VTx?= NHT0N5hRd3SnboTpZZRmeyClYX3weI91cGWlaX6tbY5lfWOnZDDjfZRwfG:6aXPpeJk> MWGyOFkxODh5Mx?=
HT-29 MUHDfZRwfG:6aXOgRZN{[Xl? MWOxNEBvVQ>? MVG3NkBp NEP6dnlFVVOR NWfBVXBFWG:2ZX70bYF1\XNiZHnnbZRwgGmwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 MkLXNlQ6ODB6N{O=
HT-29 MoniR5l1d3SxeHnjJGF{e2G7 NYnmSpdJOTBibl2= NYP4[VBtPzJiaB?= NVTreXJyTE2VTx?= M3HwVXBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M1nFblI1QTByOEez
PC3 NYLVWGI5U2mwYYPlJGF{e2G7 MYWxNFAhdk1? NGLSTnQyKGh? NGjqbWVFVVOR MX\Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= MUmyNVk4QDZ6Mx?=
PC3 MUDLbY5ie2ViQYPzZZk> M3HuOlExOCCwTR?= MUexJIg> M{HZ[WROW09? MW\Ec4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MXGyNVk4QDZ6Mx?=
PC3 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\T[mpEOS53IN88US=> MlnBNUBp MWTEUXNQ NFXNOohKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFOzJINmdGy|IIfpeIghUUN3MDDv[kA9OTBibl2= NXPpUlJDOjF7N{i2PFM>
HEK293 MXPGeY5kfGmxbjDBd5NigQ>? MnXsNVAxKG6P MY[4JIg> NIexbWFFVVOR NYHwcXlDUW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N NWPi[m0zOjF3M{mzNFE>
BT-20 MlzDT4lv[XOnIFHzd4F6 MorGNlAh|ryP NUKwR2tXTE2VTx?= NEnJclBFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= M1;ZRVIyOzV|NUWx
U937 NFS4[XpCdnSrYnHjeIVzcWGuIFHzd4F6 NIi5eWI2OCEQvF2= NYTZN2d[PDhiaB?= NHTqbpFFVVOR NFXMZo9KdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO= M2nscFIyOTR{MUC2
U937 M4rvVWFvfGmkYXP0[ZJq[WxiQYPzZZk> NHTRcVI2OCEQvF2= MmXlOFghcA>? NEnOeYxFVVOR MV3Ec4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ M3jFPVIyOTR{MUC2
U937 MX\BcpRq[mGldHXybYFtKEG|c3H5 NFzlfpo2OCEQvF2= NHHxUmc1QCCq Mo\RSG1UVw>? MlzUSI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM> NWntN41rOjFzNEKxNFY>
MCF-7 NX3IeXRWSXW2b4DoZYd6KEG|c3H5 MoHiN|Ahdk1? MWK0JIg> MYDEUXNQ NIr6c3pKdmS3Y3XzJIF2fG:yaHHnfS=> NYDRSZpVOjByMkixN|Q>
U87MG MYrLbY5ie2ViQYPzZZk> Mk\kNUDPxE1? NInHZlE3KGh? NHX4PHNFVVOR Mk\NVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NEnKbYgyQTh2OESwOC=>
U87MG NIW2co5McW6jc3WgRZN{[Xl? M{fnRVEh|ryP NETYPHY3KGh? MVXEUXNQ MXnQc5RmdnSueTDpcohq[mm2czC0SWJROSiWN{CpJJBpd3OyaH;yfYxifGmxbh?= MmXnNVk5PDh2MES=
U87MG MUnLbY5ie2ViQYPzZZk> NXjEcWNqOSEQvF2= M2\reFYhcA>? MlLDSG1UVw>? MUPEc4V{KG6xdDDpcohq[mm2IH3UU3IudWWmaXH0[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M1;BdVE6QDR6NEC0
U87MG Mom5T4lv[XOnIFHzd4F6 M3PFNFEh|ryP NUfNfWVJPiCq M33VZWROW09? MYLEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> NFvGfJEyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb M1njeWF2fG:yaHHnfUBCe3OjeR?= NWTZdXZkOC5{IN88US=> M{X2VVI1KGh? Mlj3SG1UVw>? MlTvTY5lfWOnczDheZRweGijZ4m= MVmxPFM6OTl2OR?=
COS7 cells expressing EGFP-LC3 NUTabHA6SXW2b4DoZYd6KEG|c3H5 NVOxTo1bOC5{IN88US=> M2niU|I1KGh? MVHEUXNQ NHu2R|FKdmS3Y3XzJIF2fG:yaHHnfS=> M{\EWFE5OzlzOUS5
H4 MX;GeY5kfGmxbjDBd5NigQ>? MVqwMlIh|ryP MlPjNlQhcA>? MonkSG1UVw>? M4H6VGlv[3KnYYPld{B1cGVicnH0bY8hd2ZibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFIhfG9ibHnnbJQh[2ijaX6gN{B{fWK3bnn0JFEhcW5iaIXtZY4hUDRiY3XscJM> NUjob2NEOThyMkS1PFQ>
HeLa M4fsT2Z2dmO2aX;uJGF{e2G7 Mnn2NVAxKG6P M3vHN|M3KGh? NYfPNItUTE2VTx?= MWXJcoR2[2W|IF\SRkBMOjB7NWCsJHQzODl6TDygW|IyODGIIH31eIFvfC23YnnxeYl1cW6FIHnueIVz[WO2aX;u NWXMZmpyOTd3NkOzPFU>
HeLa MlniSpVv[3Srb36gRZN{[Xl? MYqxNFAhdk1? NIC3fpg{PiCq M2qxNmROW09? M{PKTWlv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? MomzNVc2PjN|OEW=
HeLa M2fY[mZ2dmO2aX;uJGF{e2G7 MkPyNVAxKG6P MVmzOkBp MmjUSG1UVw>? NXW1NWpGUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v NHrET28yPzV4M{O4OS=>
SYF MkHQSpVv[3Srb36gRZN{[Xl? NETGO5QyODBibl2= NXLGTZpROjRiaB?= MlTjSG1UVw>? NFnreGpKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> M1fE[lE4PTZ|M{i1
SYF NFLCdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;SNVAxKG6P NWe2dHN2OjRiaB?= NGH5VopFVVOR NVvOOIRXUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHN[TiClZXzsdy=> M1f4UFE4PTZ|M{i1
HEK293T MYDBcpRqfmm{YXygRZN{[Xl? Mn3QNUBvVQ>? M3TWVlQh\A>? NFjOSW1FVVOR NHnDUIFKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> MmHDNVc1QDV3MEG=
HEK293T NITBbXVCdnSrdnnyZYwhSXO|YYm= NYPVWoRIOSCwTR?= NIriS4E1KGR? MmDySG1UVw>? NYHWeIN7UW6mdXPld{BidnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJUVZzIGi0JJdqfGhiRVO1NEBw\iByLkOgcm0> NHntbpkyPzR6NUWwNS=>
PBMC NHjhdWRHfW6ldHnvckBCe3OjeR?= NF;HXGEyKG6P M3rne|E1KGR? NWHaOVdwTE2VTx?= M1HrWnJm\HWlZYOgR2NTPSCmZX7zbZR6 MXKxO|Q5PTVyMR?=
PBMC NH:xeZFHfW6ldHnvckBCe3OjeR?= M1;HTVEhdk1? NGnjfnkyPCCm NHnTZZlFVVOR NYP1NVM6TG:nczDuc5Qh[W[oZXP0JGNZS1J2IHTlcpNqfHl? NHTwPXIyPzR6NUWwNS=>
HEK293 cells NFLXWo5McW6jc3WgRZN{[Xl? NHPReZA2OCCwTR?= NH3GbWc1PSCvaX6= NWGyXXBRTE2VTx?= MoDhTY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? NHHB[YUyPzN3MEm1Ny=>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M4niWGZ2dmO2aX;uJGF{e2G7 NUXQOG1KOTByIH7N NX6xNYNxPCCq Mne4SG1UVw>? NUjTe3Y6UW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? M2PjT|E4OTJ6Mk[y
Human mixed lymphocyte M4HC[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnTfpFmPSCwTR?= M2XyfGROW09? M2XodWlEPTB;MT62JI5ONg>? M2XiVFE3OTh3OE[1
Lewis rat lymph node cells MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[2b|Uh|ryP M1vvZWROW09? MYjJR|UxRTJwNjFOwG0> MkjTNVYyQDV6NkW=
cells from the thymus of normal BALB/c mice NGjSNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HLU|ExKG6P MWq3NkBp MXnEUXNQ NVnyNVRwUW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> M{DOZVExODJzOUS4
MRK-nu-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LOZ2lEPTB;MD64OFUheE1? M360RXNCVkeHUh?=
OCUB-M MnLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfkTWM2OD13LkK0JJBO NEfPOFVUSU6JRWK=
SF539 NUfmbHpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrnTWM2OD1zMT62JJBO MVzTRW5ITVJ?
ES4 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJzLkWgdG0> MoDSV2FPT0WU
RL95-2 M1rUfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnEZWRKSzVyPUGwO{BxVQ>? M3nCbHNCVkeHUh?=
LC-2-ad M3PjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1:ySWlEPTB;NEKzJJBO M1e1e3NCVkeHUh?=
Daudi NFO5[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTR|NDDwUS=> MlvXV2FPT0WU
NTERA-S-cl-D1 MnWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDVNVVxUUN3ME20OFMheE1? MnXPV2FPT0WU
OS-RC-2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[zbG9mUUN3ME22OVIheE1? MWLTRW5ITVJ?
VA-ES-BJ MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPSPItKSzVyPUeyN{BxVQ>? NEDGVYVUSU6JRWK=
GR-ST NGTEWY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHKTWM2OD16NE[gdG0> MlX6V2FPT0WU
SW872 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ne2lEPTB;OES2JJBO MlzqV2FPT0WU
NOS-1 Moi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILZN3dKSzVyPUi3NUBxVQ>? NFr5U5hUSU6JRWK=
MC116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoThTWM2OD17OEWgdG0> M3LEVnNCVkeHUh?=
NCI-H1355 NE[5XnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr5OG1KSzVyPUGuNFEhdk1? NIO4d3RUSU6JRWK=
RPMI-8226 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn1TWM2OD1zLkG5JI5O NHGwZ3dUSU6JRWK=
TE-15 M3XINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3X[5h2UUN3ME2xMlM3KG6P NFPhUlZUSU6JRWK=
Ramos-2G6-4C10 NEjzSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7jcINKSzVyPUGuOFYhdk1? MmToV2FPT0WU
KU812 NFnndIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3C[lA6UUN3ME2yMlAyKG6P MVfTRW5ITVJ?
EW-1 NFfTUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwMUegcm0> MXTTRW5ITVJ?
KS-1 NELlVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJwNEWgcm0> M37qcnNCVkeHUh?=
SK-LMS-1 MoLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV2yOZljUUN3ME2yMlQ6KG6P MoXMV2FPT0WU
TGBC1TKB NHm2O5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW[1TYF4UUN3ME2yMlY6KG6P M1;uSXNCVkeHUh?=
TE-6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwN{egcm0> NVTVZ|hlW0GQR1XS
ETK-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z0XGlEPTB;Mj64NkBvVQ>? MXrTRW5ITVJ?
BE-13 M325TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTJwOUmgcm0> M2rzSHNCVkeHUh?=
A3-KAW NGn6NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHsVVZKSzVyPUKuPVkhdk1? NGTiPJhUSU6JRWK=
TE-10 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m2[mlEPTB;Mz6zJI5O MYrTRW5ITVJ?
DOHH-2 NGHMdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrPPYpKSzVyPUOuN|Uhdk1? Mn7kV2FPT0WU
ES6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTnTWM2OD1|LkSzJI5O MYnTRW5ITVJ?
OPM-2 Ml3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PLUGlEPTB;ND6xOUBvVQ>? NVr6OVZxW0GQR1XS
SH-4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTRwM{Sgcm0> M3vt[nNCVkeHUh?=
NB13 NULOTG94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[yTWM2OD12LkO2JI5O M3TRbHNCVkeHUh?=
HUTU-80 NEL2Z45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDGT4V[UUN3ME20MlQzKG6P M1;ld3NCVkeHUh?=
CCRF-CEM M4jvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvacoxVUUN3ME20Mlk1KG6P M{fnUHNCVkeHUh?=
TGBC24TKB MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LqPWlEPTB;NT61NUBvVQ>? MlXPV2FPT0WU
697 MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXm2WHhUUUN3ME22MlI5KG6P MXTTRW5ITVJ?
J-RT3-T3-5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTZwNE[gcm0> M13yeXNCVkeHUh?=
KALS-1 M{fX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTY[3JUUUN3ME22MlU3KG6P M{T2SXNCVkeHUh?=
no-10 NVe3SFk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTdwMkmgcm0> M3vkb3NCVkeHUh?=
SK-NEP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjjOoxKSzVyPUiuO|khdk1? MWnTRW5ITVJ?
L-540 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFyLkSyJI5O NXzCdFAzW0GQR1XS
JiyoyeP-2003 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvWTWM2OD1zMD65OEBvVQ>? MUXTRW5ITVJ?
HH NEfVXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTFzLkO5JI5O MoHTV2FPT0WU
SR NIP4[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTFzLkS1JI5O Mn\IV2FPT0WU
QIMR-WIL MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHz3NodKSzVyPUGxMlg2KG6P MWLTRW5ITVJ?
A4-Fuk MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF|LkGyJI5O NHr5N|ZUSU6JRWK=
CESS MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLrTWM2OD1zMz6xN{BvVQ>? M2jNcHNCVkeHUh?=
KE-37 M37WUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHK0R5RKSzVyPUG2MlA4KG6P NH[xVW5USU6JRWK=
SK-UT-1 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XDTmlEPTB;MU[uPFEhdk1? NUjjSIh[W0GQR1XS
SIG-M5 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvTTWM2OD1zNz6yOUBvVQ>? M2nBZ3NCVkeHUh?=
HT NYDreGFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknuTWM2OD1zNz62JI5O MXnTRW5ITVJ?
DEL M4PkTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rMe2lEPTB;MUeuPVkhdk1? MXnTRW5ITVJ?
SK-PN-DW NYG0eFFOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHIeIdHUUN3ME2yNE4zOyCwTR?= NIXCS|BUSU6JRWK=
RPMI-8402 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHFVGlKSzVyPUKxMlc4KG6P M37ROXNCVkeHUh?=
RPMI-6666 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ2LkSyJI5O NGDndXBUSU6JRWK=
NCI-H720 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjBOHdpUUN3ME2yOU41OSCwTR?= MX;TRW5ITVJ?
EW-16 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zk[2lEPTB;Mk[uPFchdk1? Mlu1V2FPT0WU
BL-70 M3rBR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ6LkO4JI5O MVrTRW5ITVJ?
SF126 NH\RXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfYXXJKSzVyPUOwMlM5KG6P M1vIPXNCVkeHUh?=
BC-1 Ml\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTJTWM2OD1|MT6yOkBvVQ>? NXXqfZRxW0GQR1XS
MHH-PREB-1 M1HmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfSTWM2OD1|Mj60OEBvVQ>? M3HYZ3NCVkeHUh?=
A101D M1q5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTN{Lk[yJI5O M3TjNHNCVkeHUh?=
NMC-G1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTN|Lk[3JI5O Ml25V2FPT0WU
LB1047-RCC NEm0[|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj4ToxKSzVyPUO0MlY6KG6P MnfsV2FPT0WU
EM-2 M3\MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTN6LkWzJI5O NHGxe4dUSU6JRWK=
COLO-684 M{npPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN7Lkigcm0> MVnTRW5ITVJ?
Becker M3e0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF22NFBKSzVyPUSxMlA2KG6P Mmj0V2FPT0WU
BL-41 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:4ZWlEPTB;NEOuOlYhdk1? M2WzPHNCVkeHUh?=
MDA-MB-134-VI NYC0UpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTKTWM2OD12ND6wNkBvVQ>? MX7TRW5ITVJ?
L-363 M3HiS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPMUnl{UUN3ME20OE44OyCwTR?= NVznSZBWW0GQR1XS
ECC4 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLve4RKSzVyPUS0Mlc5KG6P NWnsUVlbW0GQR1XS
A388 NVHGPYV6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7wTWM2OD12ND64NkBvVQ>? NVPCb21VW0GQR1XS
HEL NUfxfok1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;EdJhGUUN3ME20PU44QSCwTR?= NHPFbndUSU6JRWK=
RKO M{W5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVyLkK5JI5O M{XZR3NCVkeHUh?=
KINGS-1 MlTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTVzLkW1JI5O NGrhb|BUSU6JRWK=
EB-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfkdIhKSzVyPUWyMlY4KG6P NXGybYp{W0GQR1XS
ARH-77 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTV{Lkigcm0> M2PucHNCVkeHUh?=
GCIY MoTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zQdWlEPTB;NUOuOFYhdk1? NVHZR2FMW0GQR1XS
NCI-H1304 NVvVdmF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDLTHVKSzVyPUW3MlIzKG6P MYLTRW5ITVJ?
KARPAS-299 MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZzLkiyJI5O NWX4OoFiW0GQR1XS
IA-LM NFLjToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\JTWM2OD14OD6xN{BvVQ>? MmXYV2FPT0WU
GI-1 M2\HTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknPTWM2OD15MD6zPUBvVQ>? M{exTnNCVkeHUh?=
TE-11 MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TZT2lEPTB;N{euNVchdk1? MnvtV2FPT0WU
LS-411N NETlOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHGxb|lKSzVyPUe3MlU4KG6P NVG5d2VDW0GQR1XS
no-11 NUXXZ4dlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfh[nVKSzVyPUizMlI1KG6P MYHTRW5ITVJ?
MV-4-11 MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTh|LkezJI5O NHr0UmdUSU6JRWK=
BV-173 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTh|Lkm3JI5O NXS2SIdLW0GQR1XS
CMK MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlP2TWM2OD16ND6xOkBvVQ>? NYXKbYtkW0GQR1XS
LC4-1 NX2wXWpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLqTWM2OD16Nj63NkBvVQ>? MljQV2FPT0WU
COR-L279 NXHL[4d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrYTWM2OD16Nz6yOUBvVQ>? M3j6[XNCVkeHUh?=
NCI-H209 NFW2T2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECyNm9KSzVyPUi3MlQyKG6P M4TvbXNCVkeHUh?=
Raji NGTlZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL4TWM2OD16OT63NkBvVQ>? M4PneXNCVkeHUh?=
LB996-RCC NEf5b3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr4VJRKSzVyPUmzMlQ{KG6P NYjFR5pyW0GQR1XS
NCI-H526 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTl|LkW5JI5O NWCxWG94W0GQR1XS
KGN M{nEdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjsTWM2OD17Nj6yPUBvVQ>? NHHCd|BUSU6JRWK=
MOLT-4 NHHIW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTl4Lke5JI5O MV7TRW5ITVJ?
PF-382 M174eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPETWM2OD17Nj63PUBvVQ>? MUjTRW5ITVJ?
BC-3 M4LPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HoXGlEPTB;OUmuNVghdk1? MYLTRW5ITVJ?
KARPAS-422 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTFyMj6wPUBvVQ>? MYnTRW5ITVJ?
SBC-1 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfEZXBrUUN3ME2xNFcvPzVibl2= M{H4OXNCVkeHUh?=
LC-1F MnPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFyOD6wOUBvVQ>? M4\MVnNCVkeHUh?=
GB-1 NF25[2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFyOT6wNkBvVQ>? NGfLdHBUSU6JRWK=
SNB75 MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DXOmlEPTB;MUG5MlY6KG6P NFXKb5RUSU6JRWK=
BB65-RCC NWTKZ4d[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLxclBYUUN3ME2xNVkvQTNibl2= MWDTRW5ITVJ?
NCI-N87 NWfYV5hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrTTWM2OD1zMkGuPVghdk1? M{\YTnNCVkeHUh?=
IST-MEL1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xlb2lEPTB;MUKyMlM5KG6P NFPITXlUSU6JRWK=
HOP-62 NHXjNZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjmTWM2OD1zMk[uPFkhdk1? NYX5SG5DW0GQR1XS
ACN MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLqTWM2OD1zNE[uO|Uhdk1? NH7BbG9USU6JRWK=
DMS-114 NGO1VllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoWxTWM2OD1zNUCuOlchdk1? Mnu0V2FPT0WU
MLMA MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3Ld2pQUUN3ME2xOVkvQDhibl2= MnzFV2FPT0WU
HT-144 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzpTWM2OD1zNkWuOFMhdk1? NVS1UWU5W0GQR1XS
C2BBe1 NU\Sb|h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TifGlEPTB;MU[3Mlc3KG6P M1PYcHNCVkeHUh?=
L-428 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTYZ2xVUUN3ME2xO|cvPyCwTR?= NVrjO4lwW0GQR1XS
DU-4475 M2TOTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XQPGlEPTB;MUi3MlY5KG6P M1nMSHNCVkeHUh?=
CP67-MEL NXHpO4ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy0eJpKSzVyPUG5PU4{QCCwTR?= MXHTRW5ITVJ?
MEG-01 NW\KOW83T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jnbGlEPTB;MkCxMlk3KG6P NWPYWXZ2W0GQR1XS
IST-SL2 MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjTNpRKSzVyPUKwPE43OyCwTR?= NUnJfYtpW0GQR1XS
ES8 NGTOV4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3DTlZKSzVyPUKyOU46PCCwTR?= MUjTRW5ITVJ?
COLO-800 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWSwPXpiUUN3ME2yN|UvOjhibl2= NWjO[HI1W0GQR1XS
MFH-ino NX60bnMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJ|NT64OEBvVQ>? NHS3dolUSU6JRWK=
OVCAR-4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTRfWp5UUN3ME2yN|cvOjRibl2= MVHTRW5ITVJ?
PSN1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnzUFlOUUN3ME2yOFIvPzFibl2= M1v4WnNCVkeHUh?=
EW-12 NHqz[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD0S2NsUUN3ME2yOFMvOSCwTR?= M{X2TnNCVkeHUh?=
HCC1599 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3hXWxCUUN3ME2yOlEvPDdibl2= NF;MVJJUSU6JRWK=
SJSA-1 NVfTbZptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPw[XA{UUN3ME2yO|EvPDZibl2= M2HNUXNCVkeHUh?=
ST486 M4PScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\HVoZKSzVyPUK5Ok4yPCCwTR?= M4H6[HNCVkeHUh?=
NOMO-1 M2PtVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S2[WlEPTB;M{CwMlIyKG6P NWH1UHptW0GQR1XS
MN-60 NEfuZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjZdG5KSzVyPUOwOU4{OiCwTR?= MnvhV2FPT0WU
HCC1187 NInpNnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTNyNz6yOUBvVQ>? MnXCV2FPT0WU
SW982 M1ji[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfscpMxUUN3ME2zNVQvPzVibl2= MWLTRW5ITVJ?
LB647-SCLC NH3XRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN{OD63NUBvVQ>? MUXTRW5ITVJ?
HC-1 NEXXSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjQdno5UUN3ME2zN|UvPSCwTR?= MXfTRW5ITVJ?
EHEB M{PjOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnYNmNKSzVyPUOzO{42OiCwTR?= M13zOHNCVkeHUh?=
TUR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDMTWM2OD1|NkOuPVUhdk1? MULTRW5ITVJ?
LU-139 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXYTWM2OD1|N{iuNFIhdk1? NUDhXYtCW0GQR1XS
NB1 MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT1dGR1UUN3ME2zPFQvPDVibl2= MnXkV2FPT0WU
BB30-HNC NGXNeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVOze414UUN3ME2zPFgvOzJibl2= Mn7DV2FPT0WU
HAL-01 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDYd2lKSzVyPUO4PU4zPiCwTR?= M3XYc3NCVkeHUh?=
K5 NFfycnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTRzMT6zO{BvVQ>? NYnZ[2V[W0GQR1XS
MZ2-MEL M3PUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PNXGlEPTB;NEGzMlY1KG6P M{DtV3NCVkeHUh?=
RXF393 M1HT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq4TWM2OD12MU[uOFUhdk1? M2nPTnNCVkeHUh?=
NCI-H1648 NX7OZnpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vVVmlEPTB;NEG3MlU{KG6P NWjLNXNFW0GQR1XS
TE-12 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHzTWM2OD12M{SuNlYhdk1? M1[0OHNCVkeHUh?=
EoL-1- NY[5R2dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTR|Nz65PEBvVQ>? MX7TRW5ITVJ?
JAR MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDkdlZKSzVyPUSzPE43OiCwTR?= NXjFVJVGW0GQR1XS
DSH1 MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTR3OD65NUBvVQ>? NVT5e5dDW0GQR1XS
NCI-H187 Mo\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF20eHFKSzVyPUS2Nk45OSCwTR?= M3Pw[HNCVkeHUh?=
HCE-4 MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTR5Nz62OkBvVQ>? MWHTRW5ITVJ?
8-MG-BA MoLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j4VmlEPTB;NUixMlUzKG6P MW\TRW5ITVJ?
KLE NWT3SGFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjrTXRKSzVyPUW4OU4zKG6P MWXTRW5ITVJ?
KNS-42 NFi2UoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7sfoVKSzVyPUW4Ok45OSCwTR?= MnnVV2FPT0WU
MSTO-211H NIO0VY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTZyOT63OEBvVQ>? M3\zSnNCVkeHUh?=
GDM-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\DTWM2OD14MUSuNFkhdk1? NGHjNG9USU6JRWK=
TE-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzCTWM2OD14NE[uNVIhdk1? M1vlR3NCVkeHUh?=
BT-474 MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:2TWM2OD14NEeuNFYhdk1? NFfGNo9USU6JRWK=
KARPAS-45 NF\4XI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTZ2Nz62JI5O NWf3[nY2W0GQR1XS
MOLT-16 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PjXGlEPTB;NkS3Mlk{KG6P MlfPV2FPT0WU
KURAMOCHI MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLGOFFKSzVyPU[1O{42OSCwTR?= M2TqNnNCVkeHUh?=
K-562 NHy4cVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTZ4OT61NUBvVQ>? MmLhV2FPT0WU
EKVX MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTZ5Mj63NUBvVQ>? MojRV2FPT0WU
GAK NV3MTXh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7uU25KSzVyPU[3OU4{KG6P MofQV2FPT0WU
NCI-SNU-5 M1XpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LXUWlEPTB;NkmwMlAyKG6P M4jqNHNCVkeHUh?=
NCI-H2126 NV3XZ4RbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHOTWM2OD15Mk[uPFchdk1? NHjDUW9USU6JRWK=
CTV-1 M{HvNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XGPWlEPTB;N{S0Mlkhdk1? M3K3d3NCVkeHUh?=
SW962 NGHmZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDTTWM2OD15NEiuOFQhdk1? MnvlV2FPT0WU
MONO-MAC-6 Mn;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPyTWM2OD15NU[uPVMhdk1? NYrWUnhQW0GQR1XS
NCI-H748 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnOT3dlUUN3ME23OVgvQTlibl2= MULTRW5ITVJ?
NCI-H524 M1HuU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXOySGVXUUN3ME23PFAvPzNibl2= MljNV2FPT0WU
LS-123 M4Py[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PIdWlEPTB;N{m1MlY6KG6P MorYV2FPT0WU
NB7 NIHoVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRThzND6xOEBvVQ>? M1;4V3NCVkeHUh?=
LS-1034 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe2bWFCUUN3ME24NlgvQThibl2= NFrKWYZUSU6JRWK=
TE-5 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPtTWM2OD16OEOuOVYhdk1? M3y2NnNCVkeHUh?=
A704 NHv4[3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPxdnpYUUN3ME24PVkvOTVibl2= NWfsZnVDW0GQR1XS
TK10 NI\Q[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvjfnhLUUN3ME25NVYvODNibl2= NEDOSVNUSU6JRWK=
NCI-H345 NV7KdpY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTl2Mz6yNkBvVQ>? M{XwZ3NCVkeHUh?=
CGTH-W-1 NGCxRpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfKTWM2OD17NEiuNVMhdk1? M{L4XXNCVkeHUh?=
NCI-H510A NVLFSoxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLISoVKSzVyPUm4OU4yOiCwTR?= MlPnV2FPT0WU
NCI-H1963 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWH1WIN6UUN3ME2xMlA{Ojl{IN88US=> MmLNV2FPT0WU
SCC-3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwMEO0NVQh|ryP M4C1OHNCVkeHUh?=
EW-11 MmTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwMEi3OFMh|ryP NHvpeIhUSU6JRWK=
CPC-N MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NECzc2pKSzVyPUGuNFg5KM7:TR?= MW\TRW5ITVJ?
NCI-H1417 M2jZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fDTWlEPTB;MT6xNlI3KM7:TR?= MkjpV2FPT0WU
DG-75 MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rnWmlEPTB;MT6xOlI5PSEQvF2= NFXERnNUSU6JRWK=
HD-MY-Z MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrXcYdKSzVyPUGuNVY1OTZizszN MkDhV2FPT0WU
ATN-1 NGHJbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rjemlEPTB;MT6yOlIxQSEQvF2= MUXTRW5ITVJ?
KM-H2 M{jHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjZeFhZUUN3ME2xMlI3PDB6IN88US=> MmTzV2FPT0WU
NCI-H2081 M3HpW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwMk[2N|ch|ryP MnvYV2FPT0WU
HL-60 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwMk[5OVkh|ryP NGi3XHZUSU6JRWK=
DB MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS0NW9KSzVyPUGuNlczPDJizszN NH;xTZpUSU6JRWK=
NCI-H1522 M4Pte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHBTWM2OD1zLkK4PFg4KM7:TR?= M1TaPHNCVkeHUh?=
AM-38 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TVVGlEPTB;MT6zNFczKM7:TR?= NVrXclVvW0GQR1XS
NCI-H446 NUXvRZpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX62fZR5UUN3ME2xMlMzOTJzIN88US=> M3;zNnNCVkeHUh?=
SU-DHL-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvLbXZpUUN3ME2xMlMzQDBzIN88US=> MlXGV2FPT0WU
NH-12 MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTFwM{[zO|Qh|ryP MWfTRW5ITVJ?
DMS-79 NWPGdHVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nrU2lEPTB;MT6zOlg3PiEQvF2= MlrvV2FPT0WU
NCI-H716 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;QTWM2OD1zLkO4PVg3KM7:TR?= NFzHPJVUSU6JRWK=
ML-2 NWS1N|B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3YTWM2OD1zLkSxOVI6KM7:TR?= Ml\QV2FPT0WU
NB10 NETRUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTFwNE[2N|Ih|ryP MWHTRW5ITVJ?
ONS-76 NHr6bXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUizfWV4UUN3ME2xMlU{PTZ7IN88US=> MnXOV2FPT0WU
LOUCY MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TaUmlEPTB;MT61OFY2PyEQvF2= NWC2T|NrW0GQR1XS
SCLC-21H M1nGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX61SlJOUUN3ME2xMlU5PTh{IN88US=> M3zPenNCVkeHUh?=
TGW M3rUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPMXpFsUUN3ME2xMlY{QTd3IN88US=> MY\TRW5ITVJ?
LXF-289 Mn;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTFwN{OyOlgh|ryP M4W2cHNCVkeHUh?=
BB49-HNC Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\jNHhKSzVyPUGuO|M2QDZizszN NUSyflZ{W0GQR1XS
NCI-H747 M{LvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELY[WdKSzVyPUGuO|U{PDZizszN NEPNe|lUSU6JRWK=
LU-165 M2DzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3hTWM2OD1zLki0PVg3KM7:TR?= NV\qNYFkW0GQR1XS
OMC-1 M4Wy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nUfGlEPTB;MT65OVA3PiEQvF2= MofNV2FPT0WU
RCC10RGB NF;ON3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3[wO2lEPTB;MT65OVgyPyEQvF2= MmK3V2FPT0WU
SW684 NUXRRXZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\DTWM2OD1zLkm2NFk6KM7:TR?= MoLvV2FPT0WU
TE-8 NWHseWlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:4TWM2OD1{LkC1OVU6KM7:TR?= NX;re3BoW0GQR1XS
SK-N-DZ Mnn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jxcWlEPTB;Mj6xN|I4PCEQvF2= MVHTRW5ITVJ?
EVSA-T M1;KPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJwMUezNVUh|ryP M2H1R3NCVkeHUh?=
KASUMI-1 NYi0d45LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\RTWM2OD1{LkG4PFE2KM7:TR?= M4DpenNCVkeHUh?=
NKM-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEi2UYFKSzVyPUKuNlU1PzJizszN NVXpO3dbW0GQR1XS
CAL-148 M174[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX5NGt4UUN3ME2yMlM{PjF2IN88US=> NELidmtUSU6JRWK=
NCI-H64 MlXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWqx[nVoUUN3ME2yMlM1OjN{IN88US=> NEj6ZXhUSU6JRWK=
KNS-81-FD MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13JcWlEPTB;Mj6zOlYzKM7:TR?= NHPuVYxUSU6JRWK=
KM12 M1fFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorwTWM2OD1{LkSwPFM6KM7:TR?= MlfUV2FPT0WU
SW954 MonZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XHcmlEPTB;Mj60O|c4QSEQvF2= MYHTRW5ITVJ?
NCI-H1395 MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PQVGlEPTB;Mj61NlY1PSEQvF2= MWHTRW5ITVJ?
DJM-1 NYXsN2JET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTJwNkC2N{DPxE1? Mo\TV2FPT0WU
COLO-668 NHf0OZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;xe5dMUUN3ME2yMlgzPjl3IN88US=> NVrHfldnW0GQR1XS
NCI-H1436 NWrkW4Y{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfCZYp4UUN3ME2yMlg2PjF3IN88US=> NIHvfnFUSU6JRWK=
LB2241-RCC NXeze|NlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTJwOE[4N|kh|ryP NFHYTZpUSU6JRWK=
GT3TKB NWLZcW9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vFVGlEPTB;Mj64PVA2PSEQvF2= MkHVV2FPT0WU
COLO-824 M2Tu[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPlXXFYUUN3ME2yMlg6PzZ6IN88US=> MUfTRW5ITVJ?
ES1 MlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nPe2lEPTB;Mj64PVg4QSEQvF2= NH3GVIFUSU6JRWK=
LB771-HNC MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi2NpI1UUN3ME2yMlkxQTR4IN88US=> NY\4fWZvW0GQR1XS
GI-ME-N M2TnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTNwMEC5NFQh|ryP M4j5T3NCVkeHUh?=
NALM-6 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPEZ5BKSzVyPUOuNFA6OzNizszN M1TGc3NCVkeHUh?=
LU-134-A NYDFZXZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwMEW0NlUh|ryP NEjXRmZUSU6JRWK=
DMS-153 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH2V|hKSzVyPUOuNFU5OjRizszN MXXTRW5ITVJ?
MZ1-PC M4XBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL1XVJKSzVyPUOuNFkxPzhizszN NH3FcoRUSU6JRWK=
NCI-H1155 M2XQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\oWI9KSzVyPUOuNVE3OSEQvF2= MWXTRW5ITVJ?
CAS-1 NVflSXh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mne3TWM2OD1|LkGzO|A4KM7:TR?= NV;hem5EW0GQR1XS
D-502MG MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGG0e3NKSzVyPUOuNVQ{QSEQvF2= MYrTRW5ITVJ?
NCI-H2141 NHvZTZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\UPYpKSzVyPUOuNVc1PTJizszN M{fWdHNCVkeHUh?=
NB6 M{TvWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HWbmlEPTB;Mz6xPFI2QSEQvF2= NYXoWFV1W0GQR1XS
NCCIT NXHqWWtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XX[WlEPTB;Mz6yNVgxQSEQvF2= M3G2e3NCVkeHUh?=
NB69 M3ziZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXobWhKSzVyPUOuN|E5QTFizszN MYTTRW5ITVJ?
JVM-2 MnXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV73UJNJUUN3ME2zMlM3PDN|IN88US=> MnzoV2FPT0WU
K052 M2HnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTNwM{e5Olgh|ryP MlH6V2FPT0WU
HCC2157 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknPTWM2OD1|LkWzNlI5KM7:TR?= NHnEdGlUSU6JRWK=
KMOE-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwNUSyOFIh|ryP NEPFNnJUSU6JRWK=
SF268 NF3OZ3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjUcWhKSzVyPUOuO|E2PTRizszN MYDTRW5ITVJ?
CHP-126 MmrFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNwN{[0OVgh|ryP MXHTRW5ITVJ?
CP66-MEL Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTuUVY{UUN3ME2zMlc6ODl2IN88US=> NIGzfo1USU6JRWK=
NCI-H69 NIHtVZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTRwMEG5N|Yh|ryP M1fSfHNCVkeHUh?=
A253 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHOxPVdKSzVyPUSuNFIyODFizszN NH[2dnJUSU6JRWK=
NB14 M{fLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHri[5dKSzVyPUSuNVA1PzlizszN NY[0XJFPW0GQR1XS
NCI-H1694 M3PpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTVTWM2OD12LkGzNVEzKM7:TR?= MYfTRW5ITVJ?
NCI-H2196 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTRwMUexOlkh|ryP MoDjV2FPT0WU
TE-9 NInJPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSxRpVRUUN3ME20MlE4PTh{IN88US=> MXLTRW5ITVJ?
D-283MED NWn6PHc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvlTWM2OD12LkG4PFQh|ryP NFfId|RUSU6JRWK=
OCI-AML2 NV[4ZnI3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\F[pJOUUN3ME20MlE6PDh7IN88US=> Mmm4V2FPT0WU
D-263MG NYjrXnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT2SJVbUUN3ME20MlIzQTZzIN88US=> NGPtNYNUSU6JRWK=
MPP-89 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTRwMkezNFQh|ryP NGfNXodUSU6JRWK=
LAMA-84 NHL4T|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37OeWlEPTB;ND6zNFQzOSEQvF2= M4\ZcHNCVkeHUh?=
LB373-MEL-D M4LCVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\FWXpqUUN3ME20MlM3Pzh7IN88US=> M4PG[HNCVkeHUh?=
UACC-257 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLxSFVKSzVyPUSuN|k2OzRizszN NVqxdHdGW0GQR1XS
MC-CAR M1zQXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULTOmpqUUN3ME20MlQ{QTlizszN MkTZV2FPT0WU
COLO-320-HSR NXrDeItbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TKbmlEPTB;ND60OFQzPyEQvF2= NHvrNnlUSU6JRWK=
P30-OHK MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrrTWM2OD12Lk[2OVgyKM7:TR?= MYnTRW5ITVJ?
UACC-812 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWO1XFJYUUN3ME20MlY6OTZzIN88US=> M2nTZXNCVkeHUh?=
CTB-1 M3naeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjIPVFKSzVyPUSuO|E2PTVizszN Ml[4V2FPT0WU
ALL-PO NXTLe2dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTRwOESwO|ch|ryP M{nIb3NCVkeHUh?=
SK-MEL-2 NYLtWGZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zJU2lEPTB;ND64Olk2PSEQvF2= MmjLV2FPT0WU
TC-YIK M3joSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\5TWM2OD12Lkm3PVQzKM7:TR?= MXfTRW5ITVJ?
NCI-H1882 NHvDXnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn1So1GUUN3ME21MlAzODBzIN88US=> NEnCTllUSU6JRWK=
MHH-CALL-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyZmlEPTB;NT6wOVA1OiEQvF2= M{Dv[HNCVkeHUh?=
U-87-MG NXLOW41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv4OppKSzVyPUWuNFk1PjZizszN NU\4[Gg1W0GQR1XS
NCI-H1092 Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTCTWM2OD13LkK2OVU2KM7:TR?= MVTTRW5ITVJ?
TE-441-T MmjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jmT2lEPTB;NT6yO|gzKM7:TR?= MY\TRW5ITVJ?
SK-MEL-1 NVzzTHl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnnUWd[UUN3ME21MlI6ODR2IN88US=> NWnJdmJ4W0GQR1XS
EW-22 NG\mUpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr1TlJTUUN3ME21MlI6PDZ4IN88US=> Mkn0V2FPT0WU
MZ7-mel M2PIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqzTWM2OD13LkSwOlkyKM7:TR?= NXO5SpNNW0GQR1XS
LP-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTVwNEGyPVEh|ryP NHn1blNUSU6JRWK=
NCI-SNU-16 NUHhWGp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jv[GlEPTB;NT62OFA4PCEQvF2= NIP6S2NUSU6JRWK=
LU-65 NEPQW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTUZlBQUUN3ME21Mlc3Ozd|IN88US=> NXLvOnBKW0GQR1XS
CW-2 NVfBbm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPkTWM2OD13Lki1PVU6KM7:TR?= M{DwN3NCVkeHUh?=
WSU-NHL M4HCN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HGTWlEPTB;NT65OVE4PCEQvF2= MWHTRW5ITVJ?
IST-MES1 M4XOeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfsWGVKSzVyPUWuPVU1PDNizszN NH\2WVZUSU6JRWK=
U-266 NW[2SItOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rr[WlEPTB;NT65PFIxOiEQvF2= MofGV2FPT0WU
TALL-1 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{C3NmlEPTB;Nj6xOFY5QCEQvF2= MlvHV2FPT0WU
Calu-6 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTZwMUWzNVYh|ryP MlrRV2FPT0WU
MMAC-SF MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LuS2lEPTB;Nj6xPFU2PiEQvF2= NXPmd5RZW0GQR1XS
NCI-H82 NVvCend6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TGV2lEPTB;Nj6yNFQ5QSEQvF2= MVXTRW5ITVJ?
RS4-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\K[2lEPTB;Nj6yOVg6PyEQvF2= MWnTRW5ITVJ?
SNU-C2B MmjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYriTYZ[UUN3ME22MlQxQTZ7IN88US=> NXWzXXY6W0GQR1XS
BOKU NUK0PY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\x[2lEPTB;Nj60O|U6PyEQvF2= NXftUJRZW0GQR1XS
C8166 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZwNUW5NVIh|ryP NIDGU2pUSU6JRWK=
D-247MG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX23NYNtUUN3ME23MlA1OzR5IN88US=> Mo\iV2FPT0WU
EW-18 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVriN3EzUUN3ME23MlA4Ojl{IN88US=> MWfTRW5ITVJ?
KG-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rsPGlEPTB;Nz62Nlc{QCEQvF2= M1\LVHNCVkeHUh?=
REH NYDGenk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4T3cmlEPTB;Nz62PFExQSEQvF2= NUTzblBwW0GQR1XS
U-698-M MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PmTWlEPTB;Nz64OFMyPSEQvF2= MnuyV2FPT0WU
KP-N-RT-BM-1 NFfydG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLhfIdKSzVyPUeuPVMxOjlizszN Ml7CV2FPT0WU
MS-1 M1r3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTdwOU[wOFEh|ryP NF3zbnFUSU6JRWK=
SNU-C1 Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHvOpR[UUN3ME23Mlk5OTl{IN88US=> NFXKNpJUSU6JRWK=
SK-MM-2 M1Lh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRThwMk[wOlUh|ryP NWDmVXpUW0GQR1XS
LAN-6 NIfOSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jQRWlEPTB;OD6zNFAxOSEQvF2= NVj4cZJ2W0GQR1XS
NEC8 M4[0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHRN4JWUUN3ME24MlMxPjlzIN88US=> MX\TRW5ITVJ?
NCI-H1770 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF73O2lKSzVyPUiuN|gxODJizszN M2rIZXNCVkeHUh?=
D-336MG NGf6e3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRThwNECxNVYh|ryP M4nmZ3NCVkeHUh?=
COLO-829 NEjGNndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33HcGlEPTB;OD60PFg4QSEQvF2= MUPTRW5ITVJ?
LS-513 M4\GNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjtSWt3UUN3ME24MlU6PTl7IN88US=> NYGwbnFJW0GQR1XS
YT M{nydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRThwNkK0Nlch|ryP Mln5V2FPT0WU
EW-24 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\FcYdKSzVyPUiuO|Y2PCEQvF2= NHvuc3hUSU6JRWK=
IST-SL1 NV7TTVlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\vRm1qUUN3ME24Mlg3PTR|IN88US=> NGLETG9USU6JRWK=
CA46 NFzRV3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRThwOUWwPVgh|ryP MXLTRW5ITVJ?
NCI-H1838 NXmyWo5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLCTWM2OD16Lkm4OlAzKM7:TR?= NXjudmFMW0GQR1XS
NCI-H719 NED5T2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf6ZZpEUUN3ME25MlI2Ojd7IN88US=> NYXJO|JbW0GQR1XS
HCE-T NX3xT29sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHjT4JKSzVyPUmuN|A5PTFizszN NFmxXYRUSU6JRWK=
A498 NVq4SlB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLXTWM2OD17LkO2NVI1KM7:TR?= MUnTRW5ITVJ?
LB831-BLC NETQXWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTlwN{[1NlEh|ryP M{fNXnNCVkeHUh?=
SKM-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKydVBKSzVyPUmuPFU6PjNizszN NWnoeng4W0GQR1XS
THP-1 NIj5N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrXTWM2OD17Lkm2PVE5KM7:TR?= MnK3V2FPT0WU
SHP-77 MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:zTWM2OD1zMD60NFch|ryP NGr5fYtUSU6JRWK=
EW-3 NYfxZ2twT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorFTWM2OD1zMD62Nlg6KM7:TR?= NHLF[XhUSU6JRWK=
KY821 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml70TWM2OD1zMD63OlMh|ryP MlrDV2FPT0WU
NCI-SNU-1 NYHFR4dRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjZdWc1UUN3ME2xNU4xOjF5IN88US=> NIDUeXhUSU6JRWK=
HCC2218 MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjoeFBKSzVyPUGxMlM6QDZizszN Mo\tV2FPT0WU
IM-9 NGTmbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXEfXlKSzVyPUGxMlUyODZizszN NHzIcWVUSU6JRWK=
NCI-H889 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[5TWM2OD1zMT61N|E{KM7:TR?= NHPMfW9USU6JRWK=
HDLM-2 M1fNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofpTWM2OD1zMj60NVU6KM7:TR?= M{LKcnNCVkeHUh?=
LB2518-MEL MnjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETjb|NKSzVyPUGyMlY5OTVizszN MYHTRW5ITVJ?
NCI-H23 NHnuelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn63TWM2OD1zMz6yOFI2KM7:TR?= M3XqcXNCVkeHUh?=
NB17 NYXxVWdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF|LkS1O|kh|ryP NIDLdGtUSU6JRWK=
NCI-H322M NYrvT3V{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHMTWM2OD1zND60NFY5KM7:TR?= MWDTRW5ITVJ?
SUP-T1 Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PX[mlEPTB;MUSuOFE{KM7:TR?= M2XZXnNCVkeHUh?=
ES3 NWqxNZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF3LkC3NFMh|ryP NXvVbYFWW0GQR1XS
ES5 NITZdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfxTWM2OD1zNT6wO|g4KM7:TR?= NFGxVoFUSU6JRWK=
NCI-H1650 M1jRc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu3XmpKSzVyPUG1MlQ6PzlizszN MWTTRW5ITVJ?
NCI-H226 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDuPYEyUUN3ME2xOU45PzZ6IN88US=> MX3TRW5ITVJ?
COR-L88 M3;B[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETZUpVKSzVyPUG2MlMyPCEQvF2= M4\yT3NCVkeHUh?=
SCC-15 NFL1UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3WeVNEUUN3ME2xOk4{QDZ7IN88US=> MnTDV2FPT0WU
GOTO NHHP[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVSxV3R{UUN3ME2xOk41Pzl|IN88US=> Ml2yV2FPT0WU
SIMA MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHmTWM2OD1zNj60PFAzKM7:TR?= NH3UXJBUSU6JRWK=
NCI-H1299 NFvqeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfJTWM2OD1zNz6xOVkyKM7:TR?= MkT4V2FPT0WU
NCI-H1581 NYTBVWlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF5LkSyNVkh|ryP NHjGSZRUSU6JRWK=
MHH-NB-11 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7TTWM2OD1zNz65Olg{KM7:TR?= MX;TRW5ITVJ?
MFM-223 MofsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DnNmlEPTB;MUiuNFU{QCEQvF2= Mof4V2FPT0WU
ES7 NXnkNYZTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYezNG0xUUN3ME2xPE42PDNzIN88US=> MXLTRW5ITVJ?
JVM-3 M1HVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;KT2RKSzVyPUG4MlcyPyEQvF2= NFTZdJZUSU6JRWK=
RL M1rZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrU[HVMUUN3ME2yNE4{QDhizszN NV[5NFM6W0GQR1XS
EC-GI-10 NH;UZXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIT5c|BKSzVyPUKxMlIxPDFizszN MmCxV2FPT0WU
LNCaP-Clone-FGC M1vJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPzTWM2OD1{MT62O|Y5KM7:TR?= NG\hOWxUSU6JRWK=
IMR-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrB[Y46UUN3ME2yNU45PDl2IN88US=> NGLEPYJUSU6JRWK=
KP-N-YS NGLVR3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPWTWM2OD1{MT64O|Uh|ryP NYC0dZVDW0GQR1XS
Mo-T M4LoZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ{LkKxPFUh|ryP Mn;SV2FPT0WU
NCI-H128 NXnTUFl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrBOY8xUUN3ME2yN{42QDV|IN88US=> NEm1TpVUSU6JRWK=
RH-1 NULwU|M1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;IUZN{UUN3ME2yN{44QDZ4IN88US=> NGn6RVFUSU6JRWK=
NCI-H2171 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zUd2lEPTB;MkSuNlQ5PSEQvF2= NF3zbmpUSU6JRWK=
RPMI-8866 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjlbHJiUUN3ME2yOk44PDJizszN MWPTRW5ITVJ?
SK-N-FI MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF;NS4NKSzVyPUK3MlM5OTFizszN M4DtZnNCVkeHUh?=
LOXIMVI Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\qW2lEPTB;MkeuPFA2OSEQvF2= NGrYdo1USU6JRWK=
P31-FUJ MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDKRppKSzVyPUOxMlU{PzRizszN M1H0e3NCVkeHUh?=
KMS-12-PE MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGK1c2NKSzVyPUS5MlU{ODJizszN MlfnV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID